Download Review: Production and functionality of active peptides from milk PDF

TitleReview: Production and functionality of active peptides from milk
File Size8.6 MB
Total Pages562
Table of Contents
                            Front cover
The Editor
Chapter 1. Nutraceuticals and Functional Foods
Chapter 2. Isoflavones: Source and Metabolism
Chapter 3. Lycopene: Food Sources, Properties, and Health
Chapter 4. Garlic: The Mystical Food in Health Promotion
Chapter 5. Grape Wine and Tea Polyphenols in the Modulation of Atherosclerosis and Heart Disease
Chapter 6. Dietary Fiber and Coronary Heart Disease
Chapter 7. Omega-3 Fish Oils and Lipoprotein Metabolism
Chapter 8. Omega-3 Fish Oils and Insulin Resistance
Chapter 9. Antioxidant Vitamin and Phytochemical Content of Fresh and Processed Pepper Fruit (Capsicum annuum)
Chapter 10. Osteoarthritis: Nutrition and Lifestyle Interventions
Chapter 11. Omega-3 Fatty Acids, Mediterranean Diet, Probiotics, Vitamin D, and Exercise in the Treatment of Rheumatoid Arthritis
Chapter 12. Skeletal Effects of Soy Isoflavones in Humans: Bone Mineral Density and Bone Markers
Chapter 13. Applications of Herbs to Functional Foods
Chapter 14. Conjugated Linoleic Acids: Biological Actions and Health
Chapter 15. Olive Oil and Health Benefits
Chapter 16. The Role of  - and  -Tocopherols in Health
Chapter 17. Probiotics and Prebiotics
Chapter 18. Exopolysaccharides from Lactic Acid Bacteria: Food Uses, Production, Chemical Structures, and Health Effects
Chapter 19. Omega-3 Fatty Acids, Tryptophan, B Vitamins, SAMe, and Hypericum in the Adjunctive Treatment of Depression
Chapter 20. Protein as a Functional Food Ingredient for Weight Loss and Maintaining Body Composition
Chapter 21. Nutraceuticals and Inflammation in Athletes
Chapter 22. Oxidative Stress and Antioxidant Requirements in Trained Athletes
Chapter 23. Coenzyme Q10: A Functional Food with Immense Therapeutic Potential
Chapter 24. Coffee as a Functional Beverage
Chapter 25. Nutraceutical Stability Concerns and Shelf Life Testing
Chapter 26. Nutraceutical and Functional Food Application to Nonalcoholic Steatohepatitis
Chapter 27. Marketing and Regulatory Issues for Functional Foods and Nutraceuticals
Back cover
Document Text Contents
Page 2

Half Title Page

Handbook of


Functional Foods
Second Edition Page i Sunday, September 24, 2006 7:48 AM

Page 281

262 Handbook of Nutraceuticals and Functional Foods

43. Ho, S.C., Wong, E., Chan, S.G., Lau, J., Chan, C., Leung, P.C. Determinants of peak bone mass in
Chinese women aged 21–40 years. III. Physical activity and bone mineral density. J Bone Miner Res
12: 1262–1271, 1997.

44. Lau, E.M.C., Suriwongpaisal, P., Lee, J.K., Das De, S., Festin, M.R., Saw, S.M., Khir, A., Torralba,
T., Sham, A., Sambrook, P. Risk factors for hip fracture in Asian men and women: the Asian
Osteoporosis Study. J Bone Miner Res 16: 572–580, 2001.

45. Davis, J.W., Novotny, R., Wasnich, R.D., Ross, P.D. Ethnic, anthropometric, and lifestyle associations
with regional variations in peak bone mass. Calcif Tissue Int 65: 100–105, 1999.

46. Prentice, A., Parsons, T.J., Cole, T.J. Uncritical use of bone mineral density in absorptiometry may
lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr 60:
837–842, 1994.

47. Ross, P.D., He, Y.-F., Yates, A.J., Coupland, C., Ravn, P., McClung, M., Thompson, D., Wasnich, R.D.
Body size accounts for most differences in bone density between Asian and Caucasian women. Calcif
Tissue Int 59: 339–343, 1996.

48. Cummings, S.R., Cauley, J.A., Palermo, L., Ross, P.D., Wasnich, R.D., Black, D., Faulkner, K.G.
Racial differences in hip axis lengths might explain racial differences in rates of hip fracture.
Osteoporosis Int 4: 226–229, 1994.

49. Nakamura, T., Turner, C.H., Yoshikawa, T., Slemenda, C.W., Peacock, M., Burr, D.B., Mizuno, Y.,
Orimo, H., Ouchi, Y., Johnston, C.C., Jr. Do variations in hip geometry explain differences in hip
fracture risk between Japanese and white Americans? J Bone Miner Res 9: 1071–1076, 1994.

50. Alekel, D.L., Peterson, C.T., Werner, R.K., Mortillaro, E., Ahmed, N., Kukreja, S.C. Frame size, ethnicity,
lifestyle, and biologic contributors to areal and volumetric lumbar spine bone mineral density in
Indian/Pakistani and American Caucasian premenopausal women. J Clin Densitometry 5: 175–186,

51. Alekel, D.L., St. Germain, A., Peterson, C.T., Hanson, K.B., Stewart, J.W., Toda, T. Isoflavone-rich
soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin
Nutr 72: 844–852, 2000.

52. Potter, S.M., Baum, J.A., Teng, H., Stillman, R.J., Shay, N.F., Erdman, J.W., Jr. Soy protein and
isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr
68: 1375S–1379S, 1998.

53. Chen, Z., Zheng, W., Custer, L.J., Dai, Q., Shu, X.-O., Jin, F., Franke, A.A. Usual dietary consumption
of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples
among Chinese women in Shanghai. Nutr Cancer 33: 82–87, 1999.

54. Kimira, M., Arai, Y., Shimoi, K., Watanabe, S. Japanese intake of flavonoids and isoflavonoids from
foods. J Epidemiol 8: 168–175, 1998.

55. Maskarinec, G., Singh, S., Meng, L., Franke, A.A. Dietary soy intake and urinary isoflavone excretion
among women from a multiethnic population. Cancer Epidemiol Biomark Prev 7: 613–619, 1998.

56. Ross, P.D., Fujiwara, S., Huang, C., Davis, J.W., Epstein, R.S., Wasnich, R.D., Kodama, K., Melton,
J., III. Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in
the U.S. Int J Epidemiol 24: 1171–1177, 1995.

57. Tsai, K., Twu, S., Chieng, P., Yang, R., Lee, T. Prevalence of vertebral fractures in Chinese men and
women in urban Taiwanese communities. Calcif Tissue Int 59: 249–253, 1996.

58. Tsai, K., Huang, K., Chieng, P., Su, C. Bone mineral density of normal Chinese women in Taiwan.
Calcif Tissue Int 48: 161–166, 1991.

59. Kin, K., Lee, E., Kushida, K., Sartoris, D.J., Ohmura, A., Clopton, P.L., Inque, T. Bone density and
body composition on the Pacific Rim: a comparison between Japan-Born and U.S.-born Japanese
American women. J Bone Mineral Res 8: 861–869, 1993.

60. Davis, J.W., Ross, P.D., Nevitt, M.C., Wasnich, R.D. Incidence rates of falls among Japanese men
and women living in Hawaii. J Clin Epidemiol 50: 589–594, 1997.

61. Somekawa, Y., Chiguchi, M., Ishibashi, T., Aso, T. Soy intake related to menopausal symptoms, serum
lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 97: 109–115,

62. Tsuchida, K., Mizushima, S., Toba, M., Soda, K. Dietary soybeans intake and bone mineral density
among 995 middle-aged women in Yokohama. J Epidemiol 9: 14–19, 1999. Page 262 Saturday, September 16, 2006 9:54 AM

Page 282

Skeletal Effects of Soy Isoflavones in Humans: Bone Mineral Density and Bone Markers 263

63. Greendale, G.A., FitzGerald, G., Huang, M.-H., Sternfeld, B., Gold, E., Seeman, T., Sherman, S.,
Sowers, M.F. Dietary soy isoflavones and bone mineral density: results from the Study of Women’s
Health across the Nation. Am J Epidemiol 155: 746–754, 2002.

64. Kardinaal, A.F.M., Morton, M.S., Bruggemann-Rotgans, I.E.M., van Beresteijn, E.C.H. Phyto-oestro-
gen excretion and rate of bone loss in postmenopausal women. Eur J Clin Nutr 52: 850–855, 1998.

65. Thompson, L.U., Robb, P., Serraino, M., Cheung, F. Mammalian lignan production from various
foods. Nutr Cancer 16: 43–52, 1991.

66. Zhang, X., Shu, X.-O., Li, H., Yang, G., Li, Q., Gao, Y.-T., Zheng, W. Prospective cohort study of soy
food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 165:
1890–1895, 2005.

67. Riggs, B.L., Khosla, S., Melton, L.J., III. A unitary model for involutional osteoporosis: estrogen
deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to
bone loss in aging men. J Bone Miner Res 13: 763–773, 1998.

68. Komulainen, M., Kroger, H., Tuppurainen, M.T., Heikkinen, A.M., Alhava, E., Honkanen, R., Jurvelin,
J., Saarikoski, S. Prevention of femoral and lumbar bone loss with hormone replacement therapy and
vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin
Endocrinol Metab 84: 546–552, 1999.

69. Cauley, J.A., Seeley, D.G., Ensrud, K., Ettinger, B., Black, D., Cummings, S.R. Estrogen replacement
therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern
Med 122: 9–16, 1995.

70. Manolagas, S.C., Jilka, R.L. Mechanisms of disease: bone marrow, cytokines, and bone remodeling:
Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305–311, 1995.

71. Scharbo-DeHaan, M. Hormone replacement therapy. Nurs Pract 21(12 Pt. 2): 1–13, 1996.
72. Beresford, S.A.A., Weiss, N.S., McKnight, B. Risk of endometrial cancer in relation to use of estrogen

combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458–461, 1997.
73. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus

progestin in healthy postmenopausal women. JAMA 288: 321–333, 2002.
74. McNagny, S.E. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med

131: 605–616, 1999.
75. Eastell, R. Treatment of postmenopausal osteoporosis. N Engl J Med 338: 736–746, 1998.
76. Kessel, B. Alternatives to estrogen for menopausal women. Proc Soc Exp Biol Med 217(1): 38–44,

77. Groeneveld, F.P., Bareman, F.P., Barentsen, R., Dokter, H.J., Drogendijk, A.C., Hoes, A.W. Duration

of hormonal replacement therapy in general practice: a follow-up study. Maturitas 29: 125–131, 1998.
78. Schneider, D.L., Barrett-Connor, E.L., Morton, D.J. Timing of postmenopausal estrogen for optimal

bone mineral density. The Rancho Bernardo Study. JAMA 277: 543–547, 1997.
79. U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary pre-

vention of chronic conditions: Recommendations and rationale. Ann Intern Med 137: 834–839, 2002.
80. Fleisch, H. Bisphosphonates in osteoporosis: an introduction. Osteoporosis Int 3: S3–S5, 1993.
81. Watts, N.B. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin N Am 27: 197–214,

82. Adachi, J.D., Bensen, W.G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D.L., Lentle,

B., Olszynski, W., St. Marie, L.-G., Tenenhouse, A., Chines, A.A. Intermittent etidronate therapy to
prevent corticosteroid-induced osteoporosis. N Engl J Med 337: 382–387, 1997.

83. Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J.,
Downs, R.W., Jr., Dequeker, J., Favus, M. Effect of oral alendronate on bone mineral density and the
incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treat-
ment Study Group. N Engl J Med 333(22): 1437–1443, 1995.

84. Karpf, D.B., Shapiro, D.R., Seeman, E., Ensrud, K.E., Johnston, C.C., Adami, S., Harris, S.T., Santora,
A.C., II, Hirsch, L.J., Oppenheimer, L., Thompson, D. Prevention of Nonvertebral Fractures by
alendronate: a meta-analysis. JAMA 277(14): 1159–1164, 1997.

85. Overgaard, K., Hansen, M.A., Jensen, S.B., Christiansen, C. Effect of calcitonin given intranasally
on bone mass and fracture rates in established osteoporosis: a dose response study. Br Med J 305:
556–561, 1992. Page 263 Saturday, September 16, 2006 9:54 AM

Page 561 Page 542 Saturday, September 16, 2006 9:54 AM

Similer Documents